Clinical Trial Detail

NCT ID NCT03007979
Title Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Washington University School of Medicine
Indications

Her2-receptor negative breast cancer

Therapies

Goserelin

Fulvestrant + Palbociclib

Palbociclib + Letrozole

Age Groups: adult senior

Additional content available in CKB BOOST